Physician profile
Imran Ashraf
NPI 1659683498
$1,846.38
in general payments reported to CMS, 2019-2025
23 companies · $203 in 2025
The $203 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $371 · 2020: $88.49 · 2021: $20.28 · 2022: $314 · 2023: $463 · 2024: $387 · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $967 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $967.44 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $698.38 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Allergan, INC. | $235.91 | 2019-2020 | |
| Janssen Biotech, INC. | $214.41 | 2019-2025 | Tremfya |
| Aimmune Therapeutics, INC. | $144.69 | 2024-2025 | Zenpep |
| Takeda Pharmaceuticals U.S.A., INC. | $73.66 | 2019-2023 | Entyvio |
| Nestle Healthcare Nutrition INC. | $63.69 | 2021-2022 | |
| Celgene Corporation | $54.51 | 2023 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.58 | 2020-2023 | Trulance, Xifaxan |
| Daiichi Sankyo INC. | $49.13 | 2019-2020 | |
| Pfizer INC. | $35.26 | 2023-2025 | |
| Integra Lifesciences Corporation | $35.03 | 2019 | |
| Pharmacosmos Therapeutics INC. | $22.25 | 2022 | |
| Alfasigma USA, INC. | $22.23 | 2020 | |
| Ferring Pharmaceuticals INC. | $21.51 | 2023 | Rebyota |
| Ethicon US, LLC | $20.56 | 2023 | Linx Reflux Management System |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $20.04 | 2024 | |
| Amgen INC. | $19.47 | 2025 | |
| Ucb, INC. | $14.64 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $14.58 | 2025 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $12.83 | 2025 | Voquezna |
| Merck Sharp & Dohme LLC | $12.09 | 2022 | |
| Ironwood Pharmaceuticals, INC | $10.93 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imran Ashraf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.